Correction: Ziemssen et al. Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod-Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC). Vaccines 2023, 11, 1374

Vaccines (Basel). 2024 Aug 12;12(8):911. doi: 10.3390/vaccines12080911.

¹ Department of Neurology, Center of Clinical Neuroscience, Carl Gustav Carus University Clinic, University Hospital of Dresden, Technische Universität Dresden, 01307 Dresden, Germany.
² Novartis Pharma GmbH, 90429 Nuremberg, Germany.
³ Institute for Immunology, University Medical Center of the Johannes Gutenberg University, 55131 Mainz, Germany.

Abstract

The authors would like to make the following corrections to this published paper [...].